Literature DB >> 19153237

Blocking interhost transmission of influenza virus by vaccination in the guinea pig model.

Anice C Lowen1, John Steel, Samira Mubareka, Elena Carnero, Adolfo García-Sastre, Peter Palese.   

Abstract

Interventions aimed at preventing viral spread have the potential to effectively control influenza virus in all age groups, thereby reducing the burden of influenza illness. For this reason, we have examined the efficacy of vaccination in blocking the transmission of influenza viruses between guinea pigs. Three modes of immunization were compared: (i) natural infection; (ii) intramuscular administration of whole, inactivated influenza virus in 2 doses; and (iii) intranasal inoculation with live attenuated influenza virus in 2 doses. The ability of each immunization method to block the spread of a homologous (A/Panama/2007/99) H3N2 subtype and a heterologous (A/Wisconsin/67/05) H3N2 subtype influenza virus was tested. We found that previous infection through a natural route provided sterilizing immunity against both homologous and heterologous challenges; thus, no transmission to or from previously infected animals was observed. Vaccination with an inactivated influenza virus vaccine, in contrast, did not prevent guinea pigs from becoming infected upon challenge with either virus. Thus, both intranasal inoculation and exposure to an acutely infected guinea pig led to the infection of vaccinated animals. Vaccination with inactivated virus did, however, reduce viral load upon challenge and decrease the number of secondary transmission events from vaccinated animals to naïve cage mates. Vaccination with a live attenuated virus was found to be more efficacious than vaccination with inactivated virus, resulting in sterilizing immunity against homologous challenge and full protection against the transmission of the homologous and heterologous viruses to naïve contacts. In conclusion, we have shown that the guinea pig model can be used to test influenza virus vaccines and that the efficiency of transmission is a valuable readout when vaccine efficacy is evaluated.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153237      PMCID: PMC2655561          DOI: 10.1128/JVI.02424-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic.

Authors:  Niall P A S Johnson; Juergen Mueller
Journal:  Bull Hist Med       Date:  2002       Impact factor: 1.314

2.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis.

Authors:  W E P Beyer; A M Palache; J C de Jong; A D M E Osterhaus
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

Review 3.  Avian influenza vaccines and therapies for poultry.

Authors:  David E Swayne
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2008-04-28       Impact factor: 2.268

4.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60.

Authors:  Hong Jin; Bin Lu; Helen Zhou; Chienhui Ma; Jackie Zhao; Chin-fen Yang; George Kemble; Harry Greenberg
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

5.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.

Authors:  J J Treanor; K Kotloff; R F Betts; R Belshe; F Newman; D Iacuzio; J Wittes; M Bryant
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

6.  The Japanese experience with vaccinating schoolchildren against influenza.

Authors:  T A Reichert; N Sugaya; D S Fedson; W P Glezen; L Simonsen; M Tashiro
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

7.  Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses.

Authors:  Carolina B López; Adolfo García-Sastre; Bryan R G Williams; Thomas M Moran
Journal:  J Infect Dis       Date:  2003-03-19       Impact factor: 5.226

8.  Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Authors:  J Talon; M Salvatore; R E O'Neill; Y Nakaya; H Zheng; T Muster; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

9.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Authors:  C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

10.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

View more
  49 in total

1.  Transmission of influenza B viruses in the guinea pig.

Authors:  Natalie Pica; Yi-Ying Chou; Nicole M Bouvier; Peter Palese
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Influenza A Virus Coinfection through Transmission Can Support High Levels of Reassortment.

Authors:  Hui Tao; Lian Li; Maria C White; John Steel; Anice C Lowen
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 3.  Predicting 'airborne' influenza viruses: (trans-) mission impossible?

Authors:  E M Sorrell; E J A Schrauwen; M Linster; M De Graaf; S Herfst; R A M Fouchier
Journal:  Curr Opin Virol       Date:  2011-09-03       Impact factor: 7.090

Review 4.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Authors:  Florian Krammer; Adolfo García-Sastre; Peter Palese
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

Review 5.  What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Consideration of Strategies to Improve the Value of Animal Models.

Authors:  Ramin Sedaghat Herati; E John Wherry
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

Review 6.  Virulence determinants of pandemic influenza viruses.

Authors:  Donna M Tscherne; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

7.  Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus.

Authors:  Seema S Lakdawala; Elaine W Lamirande; Amorsolo L Suguitan; Weijia Wang; Celia P Santos; Leatrice Vogel; Yumiko Matsuoka; William G Lindsley; Hong Jin; Kanta Subbarao
Journal:  PLoS Pathog       Date:  2011-12-29       Impact factor: 6.823

8.  Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Authors:  John Steel; Anice C Lowen; Taia T Wang; Mark Yondola; Qinshan Gao; Kester Haye; Adolfo García-Sastre; Peter Palese
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

9.  Identification of amino acids in HA and PB2 critical for the transmission of H5N1 avian influenza viruses in a mammalian host.

Authors:  Yuwei Gao; Ying Zhang; Kyoko Shinya; Guohua Deng; Yongping Jiang; Zejun Li; Yuntao Guan; Guobin Tian; Yanbing Li; Jianzhong Shi; Liling Liu; Xianying Zeng; Zhigao Bu; Xianzhu Xia; Yoshihiro Kawaoka; Hualan Chen
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823

10.  New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.

Authors:  Robert H E Friesen; Wouter Koudstaal; Martin H Koldijk; Gerrit Jan Weverling; Just P J Brakenhoff; Peter J Lenting; Koert J Stittelaar; Albert D M E Osterhaus; Ronald Kompier; Jaap Goudsmit
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.